Kim Smith, ViiV head of R&D, at GlaxoSmithKline's Investor Day
FDA expands label for ViiV's Cabenuva to cover bi-monthly administration HIV treatment
Adults living with HIV will now have the option to receive treatment just six times a year, as the FDA clears ViiV Healthcare’s Cabenuva for use every two months.
The label expansion comes just a few days after the one-year anniversary of Cabenuva’s initial approval, which marked the historic OK for a long-acting HIV treatment that can be administered once every month instead of daily.
Only those who are already virologically suppressed, have no history of treatment failure or suspected resistance to either of the active ingredients are eligible for this dosing regimen.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters